These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 20023260)

  • 1. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
    Chang H; Jiang AM; Qi CX
    Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?
    Marinelli M; Raponi S; Del Giudice I; De Propris MS; Nanni M; Intoppa S; Milani ML; Mauro FR; Guarini A; Foà R
    Am J Clin Pathol; 2011 Jan; 135(1):173-4. PubMed ID: 21173142
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
    Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
    Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
    Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
    Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia.
    Ripollés L; Ortega M; Ortuño F; González A; Losada J; Ojanguren J; Soler JA; Bergua J; Coll MD; Caballín MR
    Cancer Genet Cytogenet; 2006 Nov; 171(1):57-64. PubMed ID: 17074592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
    Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
    Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
    Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
    Zenz T; Döhner H; Stilgenbauer S
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.
    Fink SR; Smoley SA; Stockero KJ; Paternoster SF; Thorland EC; Van Dyke DL; Shanafelt TD; Zent CS; Call TG; Kay NE; Dewald GW
    Cancer Genet Cytogenet; 2006 Jun; 167(2):177-81. PubMed ID: 16737921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
    Nakagawa Y; Yamaguchi S; Hasegawa M; Nemoto T; Inoue M; Suzuki K; Hirokawa K; Kitagawa M
    Leuk Res; 2004 May; 28(5):487-94. PubMed ID: 15068902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
    Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
    Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.
    Reddy KS
    Br J Haematol; 2006 Mar; 132(6):705-22. PubMed ID: 16487171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.